Every nuclear facility wastes >95% of its neutrons at the wrong energy. We built the AI platform that computationally designs optimal neutron spectra — multiplying isotope output from existing infrastructure by 10–50×. No new reactors. No new sources. Just physics, done right.
Need more isotopes? Buy a bigger reactor. More beam current. Longer irradiation. Every facility on Earth solves the same problem the same way: maximize total flux and hope enough neutrons land at the right energy.
Most don't. >95% of neutrons arrive at energies where the target nucleus barely interacts. Billions in infrastructure, wasted on thermodynamic noise. Nobody is computationally designing the spectrum itself. We are.
NTarget atoms — fixed by your material choiceσ(E)Cross-section — fixed by quantum mechanics. Not negotiable.φ(E)Neutron energy spectrum — the only variable. The one we design with AI.vs. <1 barn at 1 MeV. A 30,000× contrast ratio — the AI finds geometries that concentrate flux exactly here.
Dense resonance structure between 6 eV and 10 keV. Multi-objective optimization across competing resonances.
Diagnostic backbone. 40,000+ US procedures/day depend on Mo-99 — with zero domestic production.
We run millions of Monte Carlo neutron transport simulations on GPU clusters, train neural surrogates on the results, then use Bayesian and evolutionary optimization to converge on designs no human could find. Every new isotope, every new source, every new customer makes the model smarter. The data compounds.
Millions of OpenMC neutron transport runs across massive parameter spaces. Brute-force the physics.
→Neural surrogates compress weeks of simulation into millisecond inference. The model gets smarter with every campaign.
→Bayesian & evolutionary search navigates a combinatorial design space no human can visualize. Hours, not months.
→AI-optimized geometries manufactured via metal & ceramic 3D printing. Ship to any neutron source on Earth.
Novartis's Lu-177 radioligand therapy hit $1.39B revenue in 2024 (+42% YoY), targeting $5B peak. First blockbuster radiopharmaceutical ever. Now every major pharma company is racing to build a radioisotope pipeline — and they all need the same scarce isotopes.
Every FDA approval multiplies demand. Every indication expansion multiplies patients. New reactors take a decade and $1B+. Spectrum shaping multiplies the output of what already exists — in weeks, not years.
Powers Pluvicto and Lutathera. 20% CAGR. Every pharma company wants in. Production already strained.
Alpha emitter, 1000× more potent than Lu-177. Market capped at $75M only because supply caps demand. The biggest bottleneck in medicine.
40,000 daily US procedures depend on a supply chain that routes through 5 aging reactors, none in America. 2024 shortage canceled procedures globally.
The spectrum is the product. The target changes — the platform doesn't. Every new isotope, every new source type, every new customer adds training data to the surrogate models. The moat compounds.
Mo-99, Lu-177, Ac-225, Tb-161 — each with unique resonance fingerprints. One platform designs optimal spectra for all of them. Higher specific activity, less waste, fewer processing steps, from the same source.
Every D-T fusion reactor must breed its own tritium. Li-6 captures at 940 barns thermal. Li-7 needs fast neutrons above threshold. Same problem, same AI — different target nucleus.
Space and defense electronics qualified under specific neutron spectra. AI-shaped beams test exact failure modes with precision no manual design achieves. DOD and NASA need this yesterday.
Long-lived waste isotopes have specific capture resonances. Spectrum-matched irradiation turns the economics of accelerator-driven transmutation from theoretical to viable.
Training surrogate models on millions of Monte Carlo sims was science fiction in 2020. OpenMC went open-source. GPU clusters dropped campaign costs by 100×. The physics was always there — the compute finally caught up.
SHINE ($779M raised, revenue since 2023), Adelphi, Phoenix — a commercial neutron market now exists. They sell neutrons. We make each neutron 20× more productive. Perfect symbiosis.
AI-optimized assemblies are complex, asymmetric, multi-material — nothing like the stacked cylinders humans design by hand. Metal and ceramic additive manufacturing makes them buildable for the first time.
Every radioligand approval multiplies isotope demand. Pluvicto alone expanded to 3 indications. 8 more drugs in pipeline. New reactors take a decade. The supply crisis is here now.
The company that owns the AI-optimized mapping from target isotope to optimal geometry sits between every neutron source and every application on Earth. That position compounds — with every new isotope, every new source, every new customer, and every simulation that makes the model smarter.